Cargando…
Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy
PURPOSE: Iron-based nanomaterials have recently been developed as excellent and potent Fenton reagents to reactive oxygen species (ROS) during chemodynamic therapy (CDT). The performance of the materials, however, can be impaired by the intrinsic antioxidant defense mechanism in organisms, such as a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487866/ https://www.ncbi.nlm.nih.gov/pubmed/34616150 http://dx.doi.org/10.2147/IJN.S329341 |
_version_ | 1784578046278238208 |
---|---|
author | Gong, Xiaodi Pu, Xin Wang, Jing Yang, Linlin Cui, Yunxia Li, Lijuan Sun, Xiao Liu, Jichang Bai, Jingfeng Wang, Yudong |
author_facet | Gong, Xiaodi Pu, Xin Wang, Jing Yang, Linlin Cui, Yunxia Li, Lijuan Sun, Xiao Liu, Jichang Bai, Jingfeng Wang, Yudong |
author_sort | Gong, Xiaodi |
collection | PubMed |
description | PURPOSE: Iron-based nanomaterials have recently been developed as excellent and potent Fenton reagents to reactive oxygen species (ROS) during chemodynamic therapy (CDT). The performance of the materials, however, can be impaired by the intrinsic antioxidant defense mechanism in organisms, such as autophagy. METHODS: The nanoscale metal-organic frameworks (nMOFs), nMIL-100 (Fe), were exploited and characterized. Also, the Fenton-like catalytic characteristics, anti-endometrial cancer (EC) effects and potential mechanisms of nMIL-100 (Fe) nanoparticles were investigated in vitro. RESULTS: The synthesized nMIL-100 (Fe) nanocatalyst catalyzed hydroxyl radicals (·OH) production in the presence of hydrogen peroxide (H(2)O(2)) and simultaneously depleted intracellular glutathione (GSH). Combining with H(2)O(2), nMIL-100 (Fe) nanoparticles exhibited enhanced cytotoxicity for EC cells, especially for progesterone treatment-insensitive KLE cells, probably due to relatively lower expression of the catalase gene. The accumulated ·OH initiated PTEN induced putative kinase 1 (PINK1)/E3 ubiquitin-protein ligase Parkin-mediated cytoprotective mitophagy in turn to partially rescue ·OH-induced cell apoptosis. Furthermore, both pretreatments of EC cells with siRNA-mediated Parkin knockdown and Mdivi-1 (a mitophagy inhibitor) addition were sufficient to ensure nMIL-100 (Fe) synergizing with H(2)O(2)-induced oxidative damages. CONCLUSION: These results suggest that the degree of mitophagy should be taken into consideration to optimize therapeutic efficiency when developing ROS based-CDT for EC cancer therapies. Therefore, a nMIL-100 (Fe)-guided, elevated ROS and overwhelmed mitophagy-mediated therapeutic strategy may have greater promise for EC therapy compared with current treatment modalities. |
format | Online Article Text |
id | pubmed-8487866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-84878662021-10-05 Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy Gong, Xiaodi Pu, Xin Wang, Jing Yang, Linlin Cui, Yunxia Li, Lijuan Sun, Xiao Liu, Jichang Bai, Jingfeng Wang, Yudong Int J Nanomedicine Original Research PURPOSE: Iron-based nanomaterials have recently been developed as excellent and potent Fenton reagents to reactive oxygen species (ROS) during chemodynamic therapy (CDT). The performance of the materials, however, can be impaired by the intrinsic antioxidant defense mechanism in organisms, such as autophagy. METHODS: The nanoscale metal-organic frameworks (nMOFs), nMIL-100 (Fe), were exploited and characterized. Also, the Fenton-like catalytic characteristics, anti-endometrial cancer (EC) effects and potential mechanisms of nMIL-100 (Fe) nanoparticles were investigated in vitro. RESULTS: The synthesized nMIL-100 (Fe) nanocatalyst catalyzed hydroxyl radicals (·OH) production in the presence of hydrogen peroxide (H(2)O(2)) and simultaneously depleted intracellular glutathione (GSH). Combining with H(2)O(2), nMIL-100 (Fe) nanoparticles exhibited enhanced cytotoxicity for EC cells, especially for progesterone treatment-insensitive KLE cells, probably due to relatively lower expression of the catalase gene. The accumulated ·OH initiated PTEN induced putative kinase 1 (PINK1)/E3 ubiquitin-protein ligase Parkin-mediated cytoprotective mitophagy in turn to partially rescue ·OH-induced cell apoptosis. Furthermore, both pretreatments of EC cells with siRNA-mediated Parkin knockdown and Mdivi-1 (a mitophagy inhibitor) addition were sufficient to ensure nMIL-100 (Fe) synergizing with H(2)O(2)-induced oxidative damages. CONCLUSION: These results suggest that the degree of mitophagy should be taken into consideration to optimize therapeutic efficiency when developing ROS based-CDT for EC cancer therapies. Therefore, a nMIL-100 (Fe)-guided, elevated ROS and overwhelmed mitophagy-mediated therapeutic strategy may have greater promise for EC therapy compared with current treatment modalities. Dove 2021-09-29 /pmc/articles/PMC8487866/ /pubmed/34616150 http://dx.doi.org/10.2147/IJN.S329341 Text en © 2021 Gong et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Gong, Xiaodi Pu, Xin Wang, Jing Yang, Linlin Cui, Yunxia Li, Lijuan Sun, Xiao Liu, Jichang Bai, Jingfeng Wang, Yudong Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy |
title | Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy |
title_full | Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy |
title_fullStr | Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy |
title_full_unstemmed | Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy |
title_short | Enhancing of Nanocatalyst-Driven Chemodynaminc Therapy for Endometrial Cancer Cells Through Inhibition of PINK1/Parkin-Mediated Mitophagy |
title_sort | enhancing of nanocatalyst-driven chemodynaminc therapy for endometrial cancer cells through inhibition of pink1/parkin-mediated mitophagy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8487866/ https://www.ncbi.nlm.nih.gov/pubmed/34616150 http://dx.doi.org/10.2147/IJN.S329341 |
work_keys_str_mv | AT gongxiaodi enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy AT puxin enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy AT wangjing enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy AT yanglinlin enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy AT cuiyunxia enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy AT lilijuan enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy AT sunxiao enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy AT liujichang enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy AT baijingfeng enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy AT wangyudong enhancingofnanocatalystdrivenchemodynaminctherapyforendometrialcancercellsthroughinhibitionofpink1parkinmediatedmitophagy |